

COMPLIANCE CERTIFICATE

Statement Date: March 31, 2025

To: JPMorgan Chase Bank, N.A., as Administrative Agent

The undersigned, a Responsible Officer of Solo Brands, LLC (the “Borrower”), hereby certifies to the Administrative Agent and the Lenders, each as defined in the Credit Agreement referred to below, as follows:

1. This Compliance Certificate is delivered pursuant to Sections 6.02(1) and 8.04 of the Credit Agreement dated as of May 12, 2021 (as amended by Amendment No. 1 dated as of June 2, 2021, Amendment No. 2 dated as of September 1, 2021 and Amendment No. 3 dated as of May 22, 2023) (the “Credit Agreement”). Capitalized terms used herein and not defined herein have the meanings assigned to them in the Credit Agreement.
2. The financial statements of the Borrower for the period ended on the Statement Date, as filed with the Securities and Exchange Commission, are delivered herewith.
3. The undersigned has reviewed the terms of the Credit Agreement and has made a reasonably detailed review of the transactions and condition of the Borrower during the accounting period covered by such financial statements, and such review did not disclose the existence of any Default or Event of Default.
4. The financial covenant analyses set forth on Schedule 1 attached hereto, for the four fiscal quarters ended March 31, 2025, giving effect to a Specified Equity Contribution, are true and accurate on and as of the date of this Compliance Certificate.

Dated: June 5, 2025

Solo Brands, LLC

By: [signature omitted: synthetic test document]

Name: Test Signatory

Title: Responsible Officer

SCHEDULE 1 TO COMPLIANCE CERTIFICATE

Financial covenant calculations for the four fiscal quarters ended March 31, 2025, giving effect to a Specified Equity Contribution. Dollars in thousands; parentheses are negative amounts or deductions.

Consolidated EBITDA (Section 1.01), four fiscal quarters ended March 31, 2025

1	Consolidated Net Income (net loss)	(192,285)
2	plus provision for taxes (clause (a)): net benefit	(2,819)
3	plus total interest expense, net (clause (b))	16,468
4	plus Consolidated Depreciation and Amortization Expense (clause (c))	27,271
5	plus non-cash impairment charges \$120,639 and inventory write-downs \$18,309 (clause (g))	138,948
6	plus non-cash equity compensation expense (clause (q))	5,580
7	plus contract termination charges, excluded as non-recurring (clause (1) of the definition of Consolidated Net Income)	15,511
8	plus restructuring charges (clause (e)), subject to the 15% cap in line 13	5,788
9	plus "run rate" cost savings from the first quarter 2025 reduction in force and distribution center closures, net of benefits realized (clause (k)), subject to the 20% cap in line 14	12,000
10	Consolidated EBITDA before the Specified Equity Contribution (sum of lines 1 to 9)	26,462
11	plus Specified Equity Contribution applied to the fiscal quarter ended March 31, 2025 (Section 8.04)	85,000
12	Consolidated EBITDA for Section 7.10 (line 10 plus line 11)	111,462
13	Cap on clause (e) add-backs: 15% of Consolidated EBITDA (line 12); line 8 is within the cap	16,719
14	Cap on clause (k) add-backs: 20% of Consolidated EBITDA (line 12); line 9 is within the cap	22,292

Total Net Leverage Ratio (Section 7.10(1))

15	Consolidated Total Debt: Term Loan \$82,500, Revolving Credit Loans \$346,322, finance lease liability \$532	429,354
16	minus unrestricted cash and Cash Equivalents netted (cash on hand \$206,394; netting capped at \$10,000)	(10,000)

17	minus pro forma prepayment of Revolving Credit Loans with the Specified Equity Contribution	(85,000)
18	Consolidated Net Debt (sum of lines 15 to 17)	334,354
19	Total Net Leverage Ratio before the Specified Equity Contribution ((line 15 plus line 16) ÷ line 10)	15.85 to 1.00
20	Total Net Leverage Ratio after the Specified Equity Contribution (line 18 ÷ line 12)	3.00 to 1.00
21	Maximum permitted (Test Period ending March 31, 2025)	3.50 to 1.00
22	In compliance after giving effect to the Specified Equity Contribution	Yes

Interest Coverage Ratio (Section 7.10(2))

23	Consolidated EBITDA (line 12)	111,462
24	Consolidated Interest Expense	16,468
25	Interest Coverage Ratio (line 23 ÷ line 24)	6.77 to 1.00
26	Minimum required	3.00 to 1.00
27	In compliance after giving effect to the Specified Equity Contribution	Yes

Cure Right (Section 8.04)

28	Specified Equity Contribution: cash common equity contributed by funds managed by Summit Partners (Permitted Holders), received by the Borrower on June 4, 2025	85,000
29	Notice designating the contribution as a Specified Equity Contribution delivered to the Administrative Agent	June 4, 2025
30	Cure Expiration Date (fifteenth Business Day after May 22, 2025, the date this Compliance Certificate was due under Section 6.02(1))	June 13, 2025
31	Specified Equity Contributions made in the four consecutive fiscal quarters ended March 31, 2025, including this one (maximum two)	1
32	Specified Equity Contributions made during the term of the Agreement, including this one (maximum five)	1
33	A further Specified Equity Contribution remains available for the fiscal quarter ending June 30, 2025	Yes

Basket capacity (Section 7.03(n)), for information

34	Consolidated EBITDA for the most recently ended Test Period (line 12)	111,462
35	General debt basket: the greater of \$16,750 and 20% of line 34	22,292

SYNTHETIC